黏膜相关淋巴组织淋巴瘤的临床研究

目的为提高对黏膜相关淋巴组织淋巴瘤（ＭＡＬＴ淋巴瘤）临床特征的认识。方法经我院确诊的ＭＡＬＴ淋巴瘤２４例,进行回顾性的临床分析研究。结果按原发部位可分为胃肠（ＧＩ）和非胃肠（ＮＯＮＧＩ）两组。ＧＩ组１８例（７５０％）,ＮＯＮＧＩ组６例（２５０％）,后者包括涎腺３例、肺２例和膀胱１例。手术治疗２１例,其中单用手术治疗１３例,术后合用化、放疗７例,合用放疗１例。单用化疗３例。随访１７例,失访７例,随访率为７０．８％。生存期４～１２１个月,平均３３个月,中位数１９个月。１７例随访病人中１６例已存活１～１０年,其中存活１年以上者占５８．８％、＞３年以上者占３５．３％、５年以上者占２９．４％、１０年以上者占５．９％。对临床分期和治疗措施与生存率比较显示差异无明显性（Ｐ＞０．０５）。结论ＭＡＬＴ淋巴瘤是非霍奇金淋巴瘤的一种独特亚型,具有起病隐匿、病程长、进展慢及患病率低、好发于中老年男性、Ｂ症状少见、易误诊为假性淋巴瘤、治疗疗效和预后良好等特征。     

慢性丙型肝炎患者自身免疫现象的初步研究

作者对４８例慢性丙型肝炎（丙肝）、３０例慢性乙型肝炎（乙肝）患者及２０例健康人分别检查了血清ＡＮＡ、ＳＭＡ和抗－ＧＯＲ。结果慢性丙肝组血清自身抗体（ＡＮＡ／ＳＭＡ）阳性率为３３．３％（１６／４８），明显高于健康人组的５％（１／２０）（Ｐ〈０．０２５）。在输血后慢性丙肝和散发性慢性丙肝中，ＡＮＡ／ＳＭＡ阳性率分别为２５．６％和６６．７％（Ｐ〈０．０５），ＡＮＡ／ＳＭＡ平均滴度分别为１：２０和１：１０     

急性心肌梗塞患者体内维生素E与脂质过氧化的关系

检测１２例急性心肌梗塞（ＡＭＩ）、２１例冠心病（ＣＡＤ）和２０例正常对照（ＮＳ）的血清维生素Ｅ（ＶｉｔＥ）、人超氧化物岐化酶（ｈＳＯＤ－１）及血浆过氧化脂质（ＬＰＯ）的代谢产物之一丙二醛（ＭＤＡ）水平。结果显示ＡＭＩ组的ＭＤＡ水平明显高于ＣＡＤ及ＮＳ组，而ＶｉｔＥ水平则显著低于ＣＡＤ及ＮＳ组，二者呈显著负相关（γ＝－０．６７，Ｐ＜０．００１）；ＡＭＩ和ＣＡＤ组的ｈＳＯＤ－１水平均明显低于ＮＳ组，但其两组间无差异，提示ＡＭＩ时ＶｉｔＥ作为主要的抗氧化剂被大量消耗，可能是ＡＭＩ发展的原因之一。     

多次小睡潜伏时间试验在诊断嗜睡症的应用

目的多次小睡潜伏时间试验（ＭＳＬＴ）客观评价嗜睡严重程度、治疗效果及鉴别诊断。方法对１２例正常人、１７例发作性睡病及１２例阻塞性睡眠呼吸暂停综合征（ＯＳＡＳ）患者进行ＭＳＬＴ检查。结果正常对照平均ＭＳＬＴ为２０．１±６．７分；快速眼动睡眠（ＲＥＭ）０．１±０．３次。发作性睡病组平均ＭＳＬＴ３．１±１．９分（与正常组比较，Ｐ＜０．０１；与ＯＳＡＳ组比较，Ｐ＜０．０５）；ＲＥＭ睡眠次数３．４±１．４次（与正常组比较，Ｐ＜０．０１；与ＯＳＡＳ组比较，Ｐ＜０．０５）。ＯＳＡＳ组平均ＭＳＬＴ５．７±３．２分，ＲＥＭ睡眠次数１．７±１．４。结论ＭＳＬＴ试验的平均睡眠潜伏时间及ＲＥＭ发生的次数对发作性睡病及ＯＳＡＳ患者的嗜睡严重程度及对发作性睡病的诊断和鉴别诊断具有临床价值     

Ⅱ型糖尿病合并高血压患者氧化损伤及抗氧化酶活性的研究

目的：评价氧化损伤及抗氧化酶活性对型糖尿病（ Ｎ Ｉ Ｄ Ｄ Ｍ）及其伴发高血压（ Ｈ Ｔ）的影响。　方法与结果：采用鲁米诺依赖的中性粒细胞化学发光法,对１３６ 例 Ｎ Ｉ Ｄ Ｄ Ｍ 患者（其中 ７０ 例不伴有 Ｈ Ｔ,６６ 例伴有 Ｈ Ｔ）及３０ 例年龄匹配的健康对照者, 检测其外周血中性粒细胞产生氧自由基（ Ｏ Ｆ Ｒ）的水平。采用化学定量法,测定其血浆脂质过氧化终末产物－ 丙二醛（ Ｍ Ｄ Ａ）的浓度及抗氧化酶－ 超氧化物歧化酶（ Ｓ Ｏ Ｄ）、谷胱甘肽过氧化物酶（ Ｇ Ｓ Ｈ Ｐｘ）的活性。 Ｎ Ｉ Ｄ Ｄ Ｍ 伴发 Ｈ Ｔ组,其 Ｐ Ｍ Ｎ┐ Ｃ Ｌ 峰值、积分和吞噬指数均明显高于 Ｎ Ｉ Ｄ Ｄ Ｍ 不伴 Ｈ Ｔ组及健康对照组;血浆 Ｍ Ｄ Ａ浓度较后两组也明显升高（ Ｐ均＜ ０．０１）; Ｎ Ｉ Ｄ Ｄ Ｍ 组及 Ｎ Ｉ Ｄ Ｄ Ｍ 伴发 Ｈ Ｔ组的血浆 Ｓ Ｏ Ｄ和 Ｇ Ｓ Ｈ Ｐｘ 活性较正常对照组均明显降低（ Ｐ均＜ ０．０１）;但与 Ｎ Ｉ Ｄ Ｄ Ｍ 组相比, Ｎ Ｉ Ｄ Ｄ Ｍ 伴发 Ｈ Ｔ组的血浆 Ｓ Ｏ Ｄ 和 Ｇ Ｓ Ｈ Ｐｘ 活性其差异无显著性（ Ｐ均＞ ０．０５）; Ｐ Ｍ Ｎ┐ Ｃ Ｌ峰值与 Ｍ Ｄ Ａ呈明显正相关（ｒ＝ ０．７４８６, Ｙ＝ １５９．８ Ｘ＋ １３２．２, Ｐ＜ ０．０１,     

抑制NO合酶上调大鼠血管α1—肾上腺素受体和三磷酸肌醇受体

探讨ＮＯ系统和血管α１－肾上腺素受体α１－ＡＲ）及三磷酸肌醇受体（ＩＰ３Ｒ）系统在高血压发病中的相互作用。方法在常规饲食中加入Ｌ－ＮＡＭＥ喂饲大鼠１或４周制备大鼠高血压模型；应用放射性配基结合实验观察α１－ＡＲ及ＩＰ３Ｒ的变化。结果应用Ｌ－ＮＡＭＥ处理一周，大鼠动脉血压升高３０（２ｍｍＨｇ（Ｐ＜０．０５），血浆ＮＯｘ含量则下降２５％（Ｐ＜０．０５）。主动脉肌膜α１－ＡＲ及肌浆网ＩＰ３Ｒ密度分别增加１２％和４０％。Ｌ－ＮＡＭＥ处理４周，大鼠血压升高７５±８ｍｍＨｇ（Ｐ＜０．０１），血浆ＮＯｘ含量下降５０％（Ｐ＜０．０１），主动脉肌膜α１－ＡＲ及肌浆网ＩＰ３Ｒ密度分别较对照组高７３％和１３７％（Ｐ＜０．０１），此时尾动脉肌膜ＡＲ及肌浆网ＩＰ３Ｒ密度亦较对照组增加５５％和５６％（Ｐ＜０．０１）。结论提示长期抑制ＮＯＳ引起大鼠持续性高血压的同时，可致大鼠血管α１－ＡＲ及ＩＰ３Ｒ明显上调。     

一氧化氮在肝损伤中作用的实验研究

材料与方法：１．动物模型的复制及分组：雄性ｗｉｓｔａｒ大鼠,随机分成六组。除正常对照组外,各组均给予１０％Ｄ－半乳糖胺（Ｄ－Ｇａ１Ｎ）０．６ｇ／ｋｇ及大肠杆菌Ｏ１１１Ｂ４脂多糖（ＬＰＳ）０．１ｍｇ／ｋｇ腹腔注射,造成大鼠急性肝损伤模型。并分别于给Ｄ－ＧａｌＮ前２０分钟及后６小时、１１小时,精氨酸（Ａｒｓ）组给子Ｌ－Ａｒｇ０．５ｇ／ｋｇ腹腔注射;Ａｒｇ一硝基精氨酸甲酯（ＮＡＭＥ）组给予Ｌ－Ａｒｇ０．５ｇ／ｋｇ加Ｌ一ＮＡＭＥ５０ｍｇ／ｋｇ;ＮＡＭＥ组给予Ｌ－ＮＡＭＥ１０ｍｇ／ｋｇ;地塞米松（Ｄｅｘ）…     

含弓形虫ROP1基因真核表达重组质粒DNA免疫小鼠的研究Ⅴ.IFN-γ基因真核表达重组质粒的构建及其在DNA免疫中基因佐剂的作用

目的　构建ＩＦＮ－γ基因真核表达重组质粒作为基因佐剂,观察其与ｐｃＤＮＡ３－ＲＯＰ１（ｐｃ－ＲＯＰ１） ＤＮＡ共同免疫小鼠所诱导的免疫应答。方法　将ＩＦＮ－γ基因片段定向插入真核表达载体ｐｃＤＮＡ３,双酶切鉴定,获得ｐｃＩＦＮ 重组子;碱裂解法大量制备,经肌肉注射免疫ＢＡＬＢ／ｃ小鼠,每只鼠注射ｐｃＩＦＮ、ｐｃ－ＲＯＰ１ 各１００μｇ,两周后同量加强免疫一次,以ｐｃＤＮＡ３空质粒及生理盐水组为对照。分别于免疫后第３０ 天、５０ 天、７０天共三次用ＭＴＴ法测定小鼠脾脏Ｔ淋巴细胞增殖活性及ＮＫ细胞活性;双夹心ＥＬＩＳＡ 测定血清细胞因子ＩＦＮ－γ、ＩＬ－２及酶法测定ＮＯ含量;ＥＬＩＳＡ法测定ＩｇＧ抗体滴度。结果　构建成功的作用下,该两项指标均明显提高,且ＩＦＮ－γ、ＩＬ－２ 及ＮＯ水平均较不加佐剂组显著提高（Ｐ＜ ０．０１）;而对ＩｇＧ抗体滴度无显著影响（Ｐ＞ ０．０５。结论　ＩＦＮ－γ基因佐剂具有协同ｐｃ－ＲＯＰ１ＤＮＡ免疫的作用,可增强免疫鼠细胞免疫应答,ＩＦＮ－γ、ＩＬ－２细胞因子及ＮＯ的产生     

谷胱甘肽-S-转移酶M1和T1空白基因型与肝癌遗传易感性的研究

目的谷胱甘肽－Ｓ－转移酶Ｍ１和Ｔ１（ＧＳＴＭ１和ＧＳＴＴ１）空白基因型与肝癌遗传易感性的关系。方法应用多重ＰＣＲ技术检测６３例肝癌患者和８８例健康对照的ＧＳＴＭ１和ＧＳＴＴ１空白基因型。结果病例组ＧＳＴＭ１空白基因型的频率为５７．１％，对照组则为４２．０％，二者差异无显著性（χ２＝３．３５，Ｐ＝０．０６７），处于临界水平。ＯＲ值为１．８４（９５％ＣＩ＝０．９１～３．７３）。病例组ＧＳＴＴ１非空白基因型的频率为８７．３％，对照组则为６２．５％，二者差异有非常显著性（χ２＝１１．４２，Ｐ＝０．０００７２７４），ＯＲ值为４．１３（９５％ＣＩ＝１．６４～１０．７０）。叉生分析表明，ＧＳＴＴ１非空白基因型与肝癌的关联大于ＧＳＴＭ１空白基因型，两因素在肝癌发生中存在协同作用。结论具有ＧＳＴＭ１空白基因型和ＧＳＴＴ１非空白基因型的个体，患肝癌的危险性增加。     

急性心肌梗死患者溶栓治疗前后血清一氧化氮含量变化

目的：探讨急性心肌梗死（ Ａ Ｍ Ｉ）患者血清一氧化氮（ Ｎ Ｏ）含量变化及其临床意义。方法：在２８例 Ａ Ｍ Ｉ患者接受尿激酶静脉溶栓治疗前及治疗后３ ｈ 分别测定其血清一氧化氮（ Ｎ Ｏ）、超氧化物岐化酶（ Ｓ Ｏ Ｄ）及丙二醛（ Ｍ Ｄ Ａ）的含量变化。结果：溶栓治疗后３ ｈ 的 Ｎ Ｏ、 Ｓ Ｏ Ｄ 含量较治疗前含量显著减少（ Ｐ ＜ ０．０５）。 Ｍ Ｄ Ａ 含量显著增加（ Ｐ ＜ ０．０５）。尤以冠状动脉再通组 Ｎ Ｏ、 Ｓ Ｏ Ｄ 含量减少（ Ｐ ＜ ０．０１）, Ｍ Ａ Ｄ 含量增加（ Ｐ ＜ ０．０１）更明显。而未通组在治疗前后的 Ｎ Ｏ、 Ｓ Ｏ Ｄ、 Ｍ Ｄ Ａ 含量无显著性差异（ Ｐ ＞ ０．０５）。结论： Ｎ Ｏ、 Ｓ Ｏ Ｄ 含量减少, Ｍ Ａ Ｄ 含量增加与缺血心肌再灌注损伤有关,在对 Ａ Ｍ Ｉ患者行溶栓治疗同时,应同时积极采取抗氧化治疗。     

Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis

Gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B cell lymphoma (DLBCL) show a spectrum of disease characterized by varying proportions of low-grade and high-grade components. While the natural history and optimum treatment for low-grade gastric MALT lymphoma and DLBCL is well established, the prognosis and optimal treatment of patients with both low- and high-grade components is not well established. The purpose of our study was to evaluate the clinical characteristics, survival outcomes, and prognostic factors of patients with gastric MALT lymphoma and gastric DLBCL. A retrospective review of patients with gastric MALT lymphoma, gastric DLBCL, or MALT lymphoma with a high-grade component treated at our centers from 1994 to 2006 was performed. Patients were divided into three categories: “pure MALT lymphoma,” “MALT lymphoma with high-grade component” (mixed), and “pure DLBCL.” Seventy-six patients were included in our study—26 with pure MALT, 22 with MALT with high-grade component (“mixed”), and 28 with pure DLBCL. Pure MALT lymphoma and mixed lymphoma patients had similar clinical characteristics, whereas pure DLBCL patients had less favorable disease characteristics with significantly poorer performance status, higher number of extranodal sites of disease, higher stage, and larger proportion of bone marrow involvement and international prognostic index (IPI) scores compared with mixed lymphoma. The majority of mixed lymphoma (72.7%) and DLBCL patients (71.4%) were treated with chemotherapy. Of patients receiving chemotherapy, a higher proportion of mixed lymphoma and DLBCL patients received anthracycline-based combination chemotherapy regimens compared with MALT lymphoma (73% vs 71% vs 8%) whereas the proportion of mixed lymphoma and DLBCL patients was similar (p = 0.919). At a median follow-up of 37 months, the 5-year overall survival was 66.9%. The 5-year overall survival was 78% for MALT lymphoma, 84% for mixed lymphoma, and 45% for DLBCL. On univariate analysis, DLBCL histology, age, performance status, serum albumin, lactate dehydrogenase, bone marrow, number of extranodal sites, stage, and IPI score were prognostic for inferior survival. On multivariate analysis, DLBCL histology remained significantly prognostic for inferior survival, independent of chemotherapy regimen (hazard ratio (HR) 6.66, 95% confidence interval (CI) 2.01–21.41, p = 0.001). Mixed histology was not prognostic for inferior survival (HR 1.13, 95% CI 0.28–4.54, p = 0.868). Other factors prognostic for inferior survival were serum albumin <37 g/L (HR 3.22, 95% CI 1.11–13.22, p = 0.034) and treatment with non-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy (HR 4.89, 95% CI 1.67–14.36, p = 0.004). In conclusion, the clinical characteristics of mixed histology MALT lymphoma are similar to low-grade MALT lymphoma and significantly different from pure DLBCL. The prognosis of mixed histology MALT lymphoma is significantly better than pure DLBCL, independent of IPI and chemotherapy regimen, and pure DLBCL histology is independently prognostic of inferior survival outcome.     

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue

A retrospective survey of patients with pathologically reviewed extragastric mucosa-associated lymphoma tissue (MALT) lymphomas from 20 institutions was performed. A total of 180 patients with histologically confirmed diagnosis of extragastric MALT lymphomas were studied. Their median age was 59 years (range, 21-92 years). Ann Arbor stage I disease was present in 115 patients (64%) and stage II disease in 16 (9%). Most cases were in the low or low-intermediate risk groups according to the International Prognostic Index (IPI). Forty-one (23%) patients had involvement of more than one extranodal site at diagnosis and in 24 cases (13%) the lymphoma presented at multiple mucosal sites (9 of them with only mucosal involvement, without bone marrow or nodal disease). Lymph node involvement was present in 21%. Patients were treated with a variety of therapeutic strategies, including chemotherapy in 78 cases. The median overall survival (OS) was not reached; the 5-year OS rate was 90% (95% CI, 82%-94%), the 5-year cause-specific survival (CSS) was 94% (95% CI, 87%-97%), and the 5-year progression-free survival (PFS) was 60% (95% CI, 50%-70%). Multivariate analysis showed that Ann Arbor stage was significantly associated with longer OS, nodal involvement with longer CSS, and favorable IPI score with better PFS. At a median follow-up of 3.4 years, 48 patients (27%; 95% CI, 20%-34%) had a relapse, 6 (3%; 95% CI, 1%-7%) showed histologic transformation, and 18 (10%; 95% CI, 6%-15%) experienced the development of a second tumor. Our data confirm the indolent nature of nongastric MALT lymphomas and the high rate of patients presenting with disseminated disease, which, when limited to mucosal sites, was not associated with a poorer outcome.     

Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan

Twenty-three patients with primary salivary gland lymphoma were diagnosed between 1990 and 2001. The sites of involvement were the parotid gland in 13, the submandibular gland in 9 and the minor salivary gland in 1. The sites of lymphoma involvement beyond the salivary glands were the cervical lymph nodes in 7, bone marrow in 3, the axillary lymph nodes in 3, the nasopharynx in 2, the abdominal lymph nodes in 2, the palate, the subconjunctiva, and the spleen in 1 each patient. Histologically, 19 patients had lymphomas of mucosa-associated lymphoid tissue (MALT) with myoepithelial sialadenitis in 13, 3 patients had diffuse large cell lymphomas and 1 had follicular lymphoma. Six patients were in stage I, 4 in II, 1 in III and 12 in IV. Eight of 23 patients (35%) had autoimmune diseases before or after the diagnosis of NHL and all suffered from MALT lymphoma. Four patients with parotid MALT lymphoma had primary or secondary Sjogren's syndrome. One each patient suffered from hyperthyroidism, systemic lupus erythematosus, membranoproliferative glomerulonephritis and cryoglobulinemia, respectively. All the 6 stage I patients had achieved complete remission (CR) without relapses 17-84 months (median 44 months) after treatment. Excluding a stage IV patient with follicular lymphoma who died at 3.5 months without treatment, CR was achieved in all of the remaining 16 patients. However, a high relapse rate (9/16, 56%) was noted in stage II-IV patients. These patients tended to relapse in the original sites, but achieved CR again after chemotherapy or radiotherapy. One patient with MALT lymphoma developed histologic transformation into diffuse large lymphoma during relapse and died of refractory disease. Overall, only 2 patients succumbed. The overall survival and relapse-free survival rates at 5 years were 94.7 and 51.4%, respectively. Thus, salivary gland lymphoma proved to be an indolent disease.     

Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the US National Cancer Database

Systemic anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma with extranodal involvement (ALCL‐E) is a rare form of non‐Hodgkin lymphoma. No large study in the literature has compared the survival outcomes among different primary extranodal sites of involvement in ALK+ ALCL‐E. We identified 1306 patients with ALK+ ALCL‐E diagnosed between 2004 and 2014 in the US National Cancer Database, among whom 387 had primary extranodal site in the chest/abdomen/pelvis, 103 in the bone, 62 in the central nervous system, 134 in the head and neck and 620 in the cutaneous/soft tissue. Younger age, lower Charlson‐Deyo score, lower clinical stage, receipt of chemotherapy and receipt of radiotherapy were predictors of longer overall survival. Patients with extranodal involvement of central nervous system and chest/abdomen/pelvis had shorter overall survival than those with involvement of head and neck, bone, and cutaneous/subcutaneous tissue after adjusting for confounding variables. We recommend treating these patients upfront with more aggressive therapy.     

Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma

BACKGROUND: (18)Fluoro-2-deoxyglucose ((18)FDG) positron emission tomography (PET) is widely used for initial staging and follow-up in patients with malignant lymphoma. While earlier studies suggested a limited role for PET in extranodal marginal zone mucosa-associated lymphoid tissue (MALT) lymphoma patients due to their non-FDG avidity, more recent reports have suggested that the issue is controversial. In the present study, we evaluated the diagnostic accuracy of PET integrated with CT (PETCT) in patients with MALT lymphoma and assessed its reliability in clinical staging and monitoring response. METHODS: Thirty-three patients with biopsy proven MALT lymphoma in 37 sites, who underwent PET/CT at diagnosis, were enrolled. Medical records, PET/CT findings and data obtained by other diagnostic procedures were reviewed. RESULTS: Common sites of MALT lymphoma were the stomach (18), lung (5), orbit (4), and parotid gland (3). PET/CT detected active disease in 18 of 33 patients (54.5%) at diagnosis. Sensitivity in gastric MALT (38.9%) was lower when compared with non-gastric MALT (75%). PET/CT detected active disease in 100% patients with advanced disease (stage III-IV) but only in 42.3% with early stage disease (I-II). The incidence of gastric FDG uptake was higher in patients showing gastric ulcer on gastroscopy than in subjects with minimal or no macroscopic findings. Of the 33 patients in the study cohort, 12 had a follow-up PET/CT which detected relapse in three patients. CONCLUSIONS: These data suggest that PET/CT is a useful tool for both, initial staging and follow-up after therapy in patients with MALT lymphoma. Its sensitivity depends on disease location and stage at initial diagnosis.     

Curative resection plus adjuvant chemotherapy for early stage primary gastric non-Hodgkin's lymphoma: a retrospective study with emphasis on prognostic factors and treatment outcome

BACKGROUND: There is controversy regarding the optimal therapy for primary non-Hodgkin gastric lymphoma with some authors defending surgical extirpation either alone or in association with radiotherapy and or chemotherapy, especially in relation to the earlier stages of the disease. AIM: To analyze the clinical-pathological features and the results of management approaches for patients with primary early-stage non-Hodgkin's lymphoma of the stomach operated in Surgical Gastroenterology Department, "Hospital do Servidor Público Estadual", S?o Paulo, SP, Brazil. The literature is reviewed to highlight the aspects of diagnosis, prognostic factors and role of the various treatment regimens. METHOD: Sixteen patients with primary early-stage gastric lymphoma underwent curative surgical treatment. The variables analyzed were age, sex, location, size, type of surgery, number of lesions, depth of invasion, histological type in accordance with Kiel's classification, involvement of lymph nodes, Ann Arbor stage classification modified by Musshoff and Schmidt-Vollmer, histological grade, margins, adjuvant therapy, clinical course and survival. RESULTS: Ten patients (62.5%) underwent subtotal gastrectomy and six (37.5%) underwent total gastrectomy. The majority (9/56.2%) of the lesions were located in the antrum. Single lesions (10/62.5%) were more frequent than multiple lesions (6/37.5%). Thirteen patients (81.2%) were classified as stage IE and three (18.7%) as stage IIE1. Primary gastric lymphoma classified histologically as low or high grade was presented by 10 (62.5%) and 6 (37.5%) patients, respectively. The most frequent histological types were the lymphoplasmocytic cytoid (4/25.0%) and centroblastic (4/25.0%). Ten patients (62.5%) received adjuvant treatment (chemotherapy and/or radiotherapy). Nine patients (56.2%), all in stage IE, reached a survival greater than 5 years and of these eight (50.0.%) had received adjuvant therapy. Two (12.5%) patients with stage IIE1 presented peritoneal relapse and died 3.0 years and 3.5 years after their respective operations. The mean overall survival was 42.5 months. CONCLUSIONS: Among the patients with primary early-stage gastric lymphoma (IE and IIE1), the gastric resection enabled an accurate clinicopathological staging, in addition to obtaining sufficient material for histopathological study and extirpation of the lesion. Furthermore, for patients with stage IE disease, the gastric resection combined with adjuvant therapy was associated with a greater than 5-year survival. Until prospective randomized studies are realized in order to evaluate the real efficacy of the different types of treatment for primary early-stage gastric lymphoma, management approaches should be individually tailored.     

Subcutaneous dissemination pattern in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma

Background

Mucosa-associated lymphoid tissue (MALT) lymphoma is among the most common forms of extranodal lymphomas, but little is known about subcutaneous involvement in patients with non-primary cutaneous marginal zone lymphomas.

Design and Methods

Patients with MALT lymphoma diagnosed and treated at our institution between 1999 and 2010 were analyzed for subcutaneous deposits from MALT lymphoma diagnosed in another organ. Histological, clinical and genetic findings were assessed.

Results

Among 216 patients with MALT lymphoma, 12 had subcutaneous deposits from MALT lymphoma (5.5%). In two patients, these lesions were present at diagnosis, while they constituted the site of relapse at an interval between 5 to 144 months in the remaining cases. Interestingly, nine of the 12 patients with subcutaneous deposits had originally been diagnosed with MALT lymphoma of the ocular adnexa (total number=51; 20%), and the other three had MALT lymphoma in the breast (total number=5; 60%). None of the patients with gastric (n=86), salivary gland (n=32) or pulmonary (n=19) MALT lymphomas had subcutaneous involvement during a median follow-up time of 87 months (range; 4 to 119 months).

Conclusions

Our data show that subcutaneous MALT lymphoma involvement is a rare event in patients with prior non-cutaneous extranodal marginal zone lymphoma. However, it seems to be almost exclusively associated with MALT lymphoma of the ocular adnexa and the breast, suggesting as yet undefined interactions between potentially embryonically related organ systems.     

Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases

The purpose of this retrospective study, the largest unselected series in our country, was to illustrate the clinicopathological features of non-Hodgkin's lymphoma (NHL) classified according to the World Health Organization (WHO) classification of lymphoid neoplasms. A retrospective analysis was conducted and clinical features of histological subtypes were established in 810 patients (age > or = 15 years) with NHL who were treated at 8 major centers representative of Greece. There were 435 males and 375 females 95% of them aged >30 years. B symptoms were present in 34% of the patients, while 45.3% had stages I-II and 54.6% had stages III-IV. LDH was increased in 37% of the patients. B cell lymphomas formed 88% of the cases whereas T cell lymphomas formed 12% of the total. Indolent lymphomas accounted for 31.1%, aggressive ones for 66.7% and very aggressive ones for 2.4% of all NHLs. Among indolent lymphomas extranodal ones (MALT B cell lymphoma) were the most common subset while follicular lymphoma grade I and II and small lymphocytic ones presented with equal frequency. Among the aggressive lymphomas diffuse large cell lymphoma (DLCL) was the most common subtype; this entity along with large-cell immunoblastic lymphomas accounted for 45.2% of all B cell lymphomas. Among the T cell lymphomas, peripheral T cell lymphomas and anaplastic large cell lymphomas of the T/null-cell type were the most common subtypes. The most common extranodal presentation was the gastrointestinal tract (GI). Next in frequency were primary extranodal NHL of the head and neck region. MALT B cell lymphomas were found in almost half of the patients with GI tract NHL, whereas in all other extranodal places DLCL was the predominant histological subtype. The median survival for indolent and aggressive NHL was 123.5 and 55.5 months, respectively. This is the first report of a large series of malignant lymphomas in Greece using the WHO classification. It appears that there are no significant differences between NHL in Greece and other large series as far as clinical and extranodal presentation is concerned. The frequency of follicular lymphoma in the current study is comparable to that reported from Asian countries and mainland Europe, but lower than that of US and Northern European series. There were no important differences in the incidence of the remaining histological subtypes between Greece and other European countries.     

A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single center experience

Extranodal involvement is common in patients with Burkitt lymphoma (BL). We evaluated the pattern of extranodal involvement and its impact on clinical outcomes in a single center cohort of adult Korean patients with sporadic BL. We retrospectively identified 64 patients with BL in the registry of non-Hodgkin lymphoma of the Asan Medical Center between 1996 and 2009. We assessed their clinical features and distribution of extranodal sites and analyzed clinical outcomes, including complete response rate after chemotherapy, overall survival, and progression-free survival, relative to baseline characteristics and involved extranodal sites. Extranodal involvement was found in 57 patients (89?%), with 34 (53.1?%) having two or more extranodal sites. The stomach (26.6?%) was the most common site, followed by the small and large intestines (25?%), bone marrow (23.4?%), genitourinary tract (21.9?%), and bones (18.8?%). Two patients (3.1?%) showed central nervous system (CNS) involvement. Complete response rates to chemotherapy were not related to sites of extranodal involvement. Two-year overall survival rates were lower in patients with bone marrow (33.3 vs. 74.6?%, p?=?0.010) and CNS (0.0 vs. 66.6?%, p?=?0.048) involvement than in patients with involvement at other extranodal sites. The stomach, genitourinary tract, and bones were the most commonly involved extranodal sites in Korean BL patients, but site had no prognostic significance.